A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer

British Journal of Cancer

Volumn 73, Issue 10, 1996, Pages 1260-1264

  Evans, T R J ^a   Lofts, F J ^a   Mansi, J L ^a   Glees, J P ^a   Dalgleish, A G ^a   Knight, M J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

5 fluorouracil; Cisplatin; Epirubicin

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FATALITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINORRHEA; SEPSIS; STOMATITIS; VOMITING;

EID: 0029900438     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.241     Document Type: Article

References (27)

1. ANDERSON NR. (1993). 5-Fluorouracil: a re-appraisal of optional delivery in advanced breast cancer. J. Infusional Chemother., 3, 111-118.
2. BERN MM, LOKICH JJ, WALLACH SR, BOTHE A, BEROTTI PN, ARTIN CF, GRECO FA, HUBERMAN M AND MOORE C. (1990). Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann. Intern. Med., 112, 423-428.
3. BERNARD S, NOBLE S, WILCOSKY T, ATILGREN J, AND SMITH FP. (1986). A phase II study of ifosfamide (IFOS) plus N-acetyl cysteine (NAC) in metastic measurable pancreatic adenocarcinoma (abstract). Proc. Am. Soc. Clin. Oncol., 5, 328.
4. BUROKER T, KIM PN, GROPPE C, MCCRACKEN J, O'BRYAN R, PANETTIERE F, COSTANZI J, BOTTOMLEY R, KING GW, BONNET J, THIGPEN T, WHITECAR J, HANS C, VAITKEVICUS VK, HOOGSTRATEN B AND HEILBURN L. (1979). 5-FU infusion with mitomycin C vs 5-Fu infusion with methyl CCNU in the treatment of advanced upper gastrointestinal cancer. Cancer, 44, 1215-1221.
5. CALVERT AH, NEWELL DR, GUMBRELL LA, O'REILLY S, BURNELL M, BOXALL FE, SIDDIK ZH, JUDSON IR, GORE M, AND WILTSHAW E. (1989). Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7, 1748-1756.
6. CANCER OF THE PANCREAS TASK FORCE GROUP. (1981). Staging of cancer of the pancreas. Cancer, 47, 1631-1637.
7. CARTER SK. (1975). The intergration of chemotherapy into a combined modality approach for cancer treatment: VI. Pancreatic adenocarcinoma. Cancer Treat. Rev., 3, 193-214.
8. FINDLAY M, CUNNINGHAM D, NORMAN A, MANSI J, NICOLSON M, HICKISH T, NICOLSON V, NASH A, SACKS N, FORD H, CARTER R AND HILL A. (1994). A phase II study in advanced gastro-esophageal cancer using epiruhicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol., 5, 609-616.
9. JONES AL, SMITH IE, O'BRIEN MER, TALBOT D, WALSH G, RAMAGE F, ROBERTSHAW H AND ASHLEY S. (1994). Phase II study of continuous infusion 5-fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active regimen. J. Clin. Oncol., 12, 1259-1265.
10. KOVACH JS, MOERTEL CG, SCHUTT AJ, HAHN RG AND REITEMEIER RJ. (1974). A controlled study of combined 1, 3-bis-(2-chlorethyl)-1-nitrosurea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer, 33, 563-567.
11. LEONARD RCF, CULL A, STEWART ME, KNOWLES G, CARTER DC AND PALMER KR. (1992). FAM chemotherapy prolongs survival in pancreatic cancer; Quality of life is unimpaired. (abstract). Annal. Oncol., 3, (suppl. 5), 24, 92.
12. LOKICH JJ, AHLGREN JD, GULLO SJ, PHILIPS JA AND FRYER JG. (1989). A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program Study. J. Clin. Oncol., 7, 425-432.
13. MALLINSON GN, RAKE MO, COCKING JB, FOX CA, CWYNARSKI MT, DIFFEY BL, JACKSON GA, HANLEY J AND WASS VJ. (1980). Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br. J. Med. J., 281, 1589-1591.
14. MILLER AB, HOOGSTRATEN B, STAQUET M AND WINKLER A. (1981). Reporting results of cancer treatment. Cancer, 47, 207-214.
15. MOERTEL CG. (1976). Chemotherapy for gastrointestinal cancer. Clin. Gastroenterol., 5, 777-793.
16. OSTER MW, GRAY R, PANASCI L AND PERRY MC. (1986). Chemotherapy for advanced pancreatic cancer: A comparison of 5-fluorouracil, adriamycin and mitomycin - c (FAM) with 5-fluorouracil, streptozotocin and mitomycin-C (FSM). Cancer, 57, 29-33.
17. PALMER KR, KERR M, KNOWLES G, CULL A, CARTER DC, AND LEONARD RCF. (1994). Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg., 81, 882-885.
18. ROTHMAN H, CANTRELL JE JR., LOKICH J, DIFINO S, HARVEY J, AHLGREN J AND FRYER J. (1991). Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A mid-Atlantic Oncology Program Study. Cancer, 68, 264-268.
19. ROUGIER P, ZARBA JJ, DUCREUX M, BASILE M, PIGNON JP, MAHJOUBI M, BENAHMED M, DROZ JP, CVITKOVIC E AND ARMAND JP. (1993). Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Annal. Oncol., 4, 333-336.
20. SACK GH JR, LEVIN J AND BELL W. (1977). Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Clinical, pathologic and therapeutic features. Medicine, 56, 1-37.
21. SCANLON KJ, NEWMAN EM, LU Y AND PRIEST DG. (1986). Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl Acad. Sci. U.S.A., 83, 8923-8925.
22. SPROULE EE. (1938). Carcinoma and vericus thrombosis. The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am. J. Cancer, 34, 566-585.
23. STACEY RGW, FILSHIE J AND SKEWES D. (1991). Percutaneous insertion of Hickman-type catheters. Br. J. Hosp. Med., 46, 396-398.
24. TRAVE F, RUSTUM YM AND GORANSON J. (1985). Synergistic antitumour activity of cisplatin (DDP) and 5-fluorouracil (FUra) in mice bearing leukemia C1210 cells. Proc. Am. Assoc. Cancer Res., 25, 1270.
25. WILLIAMSON RCN. (1988). Pancreatic Cancer: the greatest oncological challenge. Br. Med. J., 296, 445-446.
26. WILS J, BLEIBERG H, BLIJHAM G, DALESIO O, DUEZ N, LACAVE A AND SPLINTER T. (1985). Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur. J. Cancer Clin. Oncol., 21, 191-194.
27. WILS J, KOK T, WAGENER OJ, SELLESLAGS J AND DUEZ N. (1993). Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J. Cancer, 29, 203-204.